 Johnson Johnson NYSE: JNJ just took a big step into the field of immunology with a 6.5 billion deal for Momenta Pharmaceuticals NASDAQ: MNTA. On Tuesday, the giant healthcare conglomerate announced a definitive agreement to acquire the biotech for 52.50 per share. The healthcare conglomerate is eager to expand its presence in Cambridge, Massachusetts, the worlds leading hub for biopharmaceutical innovation and the location of Momentas headquarters. 